CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Ixabepilone +3 moredrug
Likely dose
Ixabepilone 40 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00832117
NCT00832117Phase 1Completed
CompareCT.gov

Phase 1 Study of Ixabepilone in Combination With Cisplatin in Subjects With Advanced Solid Tumors

R-Pharm·interventional·Posted Jan 29, 2009·Updated Oct 28, 2020

In Brief

A Phase 1 clinical trial evaluating Ixabepilone and Cisplatin for Non Small Cell Lung Cancer. Completed, enrolled 30 participants across 7 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the effects (good or bad) on your cancer will also be studied

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesItaly, United States
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 29, 2009
Enrollment StartMay 1, 2009
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.4 years ago

Interventions

Ixabepilonedrug

Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months

Cisplatindrug

Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months

Ixabepilonedrug

Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months

Cisplatindrug

Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months